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Summary 
Experimental allergic encephalomyelitis (EAE) is an autoimmune disease that can be induced 
in laboratory animals by immunization with the major myelin proteins,  myelin basic protein 
(MBP) and proteolipid protein (PLP). We analyzed the role of the T cell receptor (TCR) repertoire 
in susceptibility to EAE induced by these two autoantigens.  Autoreactive T cells induced after 
immunization with MBP use a limited set of TCR.  In contrast, we demonstrate that T cell 
clones that recognize the encephalitogenic PLP epitope (PLP 139-151) use diverse TCR genes. 
When the TCR. repertoire is limited by introduction of a novel rearranged TCR V/~ 8.2 chain 
in transgenic  SJL mice, EAE could be induced in the transgenic mice by immunization with 
the encephalitogenic epitopes of PLP, but not with the encephalitogenic epitope of MBP. Thus, 
skewing the TCR repertoire affects the susceptibility to EAE by immunization with MBP but 
not with PLP. These data demonstrate the biological consequences of the usage of a more diverse 
T  cell repertoire  in the development  of an autoimmune disease. 
E 
xperimental autoimmune encephalomyelitis (EAE), an 
animal model of human multiple sclerosis (MS) (1), can 
be induced in laboratory animals by immunization with the 
major myelin proteins, myelin basic protein (MBP) or my- 
elin proteolipid  protein (PLP) (2, 3). The EAE that results 
from immunization with MBP is mediated by T cells that 
utilize limited sets of TCR (4-6).  PLP, which constitutes 
the bulk of the myelin proteins in the central nervous system 
(CNS),  is an equally important candidate antigen for MS. 
A panel of T cell clones specific  for the encephalitogenic epi- 
tope of PLP 139-151 was recently isolated and characterized 
(7). Cloning and sequencing of the TCR genes reveals that 
diverse TCR c~/~ chains are used by these clones. We dem- 
onstrate the consequence of the diversity of TCR gene usage 
in response to PLP and MBP by analyzing the effect  of skewing 
the TCR repertoire  on the pathogenesis  and susceptibility 
to EAE in SJL-TCR. V/3 8.2 transgenic  mice. 
Materials and Methods 
Animals.  Female  SJL/J mice  (4-8-wk-old)  were from the Jack- 
son Laboratory  (Bar Harbor, ME). Transgenic  mice  were  produced 
by injecting  the TcR/~  chain  construct (V/~ 8.2-D/31.1-JBI.I-CB2) 
(8), derived  from  an OVA-specific  T cell  hybridoma,  into the product 
of a (C57BL/6 x  SJL)F: mating. The founder animal was back- 
crossed twice to SJL/J mice and the offspring were H-2 typed. 
The H-2  s/~ homozygotes  were  then backcrossed  an additional  four 
times to SJL/J mice. This strain was termed  SJL transgenic and 
was maintained  by backcrosses  to SJL mice.  In all experiments,  non- 
transgenic mice were littermates of transgenic mice. 
Antigens.  Whole mouse myelin  was prepared  from the brains 
and spinal cords by the method of Norton and Poduslo (9). The 
MBP and PLP peptides used in the study were: MBP 89-101 
(VHFFKNIVTPRTP), MBP 17-27 (TASTMDHARH),  MBP 1-11 
(ASQKR.PSQRHG), MBP 35-47 (TGILDSIGRFFSG), PLP 139- 
151  (HSLGKWLGHPDKF), PLP  178-191 (NTWTTCQSIAF- 
PSK), and PLP 103-116 (YKTTICGKGLSATV).  Peptides  were  syn- 
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sity, Boston, MA) or by Hans Freisheim (Medical College of Ohio, 
Toledo, OH). 
Antibodies.  The following antibodies  were used: anti-V38.1 and 
8.2 (KJ 16-133, obtained from Phillipa Marrack and John Kappler, 
National Jewish Center of Immunology and Respiratory Medi- 
cine, Denver, CO);  anti-V36 (46-6-B5, from Hans Hengartner, 
University of Zurich, Zurich, Switzerland); anti-V/~4 (KT 10.4, 
from Dr. Robert Clark, University of Connecticut, Farmington, 
CT); anti-V~11 (RR 3-15, from Dr. Ed Palmer, National Jewish 
Center of Immunology  and Respiratory Medicine); and anti-CD4 
(GK 1.5, from Dr. Frank Fitch, University  of  Chicago, Chicago, IL). 
T Cell Clones and Hybridomas.  The five T cell clones used have 
been described (7). Hybridomas were prepared (10) from each of 
the clones and were used to isolate some TCR genes. 
Cloning and Sequendng of TCR Genes.  Full-length  cDNA clones 
for TCR~ from 5B6, 7A5, and 4E3 and for TCR3 from 7A5 and 
4E3 were isolated  from unamplified  XZap (Stratagene, La  Jolla, CA) 
libraries, and the DNA sequence of multiple clones were deter- 
mined. The SPLI.1 TCRoe was identified using inverse PCR (11) 
using two Cc~ primers. The full-length cDNA clone was then iso- 
lated by using a primer specific for the predicted Vcd5 leader se- 
quence  (AAATTTGAATTCATGAAGACATCCCTTCACACT- 
GTA) with 3' Cc~ (AAATTTGAATTCAACTGGACCACAGCC- 
TCA) primers. The 2E5 TCRc~  clone was identified  by PCR using 
a degenerate Vc~ primer (12) and a Cc~ primer and independently 
cloned by PCR with the above Veal5 and Cc~ primers and se- 
quenced. The 2E5 and SPLI.1 TCR 3 chains were isolated  by PCR 
with a V317a specific  primer (ATGGGTGCAAGACTGCTCTGC- 
TGTGTAGCA) or V32  primer  (ATGTGGCAGTTTTCCATT- 
CTGTGCCTCTGC), and a 3' C3 (AAATTTGAATTCTGATGT- 
TCTGTGTGACAGGT) primer. The 5B6 TCR3 clones were iso- 
lated by PCR using a degenerate V3 oligonucleotide (13) and the 
3' C3 primer; sequence  of clones from a second  PCR reaction with 
V~6 and C3 primers confirmed that this was derived from a full- 
length transcript. 
In Vitro Proliferation.  Mice  were immunized subcutaneously  with 
100/zg of PLP or MBP peptides in 0.1 ml of CFA containing 200 
/~g of heat killed Mycobacterium tuberculosis H37RA (Difco Labora- 
tories, Detroit, MI). Cells from inguinal, prescapular, and para- 
aortic lymph  nodes were dissociated and cultured at  5  x  10  s 
cells/well with peptide in DMEM (GIBCO BRL, Gaithersburg, 
MD) containing 10% FCS in 96-well  plates for 72 h and then pulsed 
with 1 #Ci of [3H]thymidine  for 16-18 h. Mean thymidine incor- 
poration from triplicate wells was calculated.  Antibodies were used 
as culture supernatants for blocking studies. 
EAE Studies.  Mice  were injected subcutaneously in the flank 
with 2 mg of whole mouse myelin or 50 or 70 nmol of peptide 
and 400/~g of M. tuberculosis H37Ra (Difco) in an emulsion con- 
sisting of equal volumes of water and CFA. Each mouse was also 
injected intravenously on day 0 and days 2, 3, or 4 with 109 heat 
killed Bordetella ioertussis bacilli (Pertussis vaccine  lot no 264; Mas- 
sachusetts Public Health Biological Laboratories, Boston, MA) or 
200 ng pertussis toxin (List Biological Laboratories, Inc., Camp- 
bell, CA). Clinical assessment  was carried out daily as described (7). 
Brains and spinal  cords were removed  and fixed  in 10% phosphate- 
buffered formalin, and paraffin-embedded  sections were stained for 
light microscopy. Histological disease was quantified by counting 
inflammatory loci in meninges and parenchyma (7). For evaluation 
of TCR V/~ expression in the tissues, the brains and samples of 
spleen and thymus were frozen in OCT compound (Miles Labora- 
tories, Naperville, IL) and stored at - 70~  4-6/zm-thick cryostat 
tissue sections were immunostained with undiluted anti-TCR V3 
hybridoma  culture  supernatants  using  avidin-biotin immuno- 
histochemical staining kits (Vector  Laboratories,  Inc., Burlingame, 
CA). 
Results and Discussion 
We examined TCR usage in a panel of T cell clones specific 
for the encephalitogenic PLP epitope 139-151 (7). These PLP- 
specific T cell clones use a variety of TCR Vot, Jot and V3, 
D3, and J3 segments (Fig. 1). Two of the T cell clones (2E5 
and SPLI.1)  used the same Vot15 segment in combination 
with different Jot segments, thereby creating diverse junc- 
tional regions. The Jot8 segment was used by clones SPLI.1 
and 5B6 in combination with different Vot segments. The 
V3 segments were all different, with only two of the clones 
using the same J3 segment. A  conserved junctional motif 
was not observed  in the CDR3 region of the TCR ot or 
chains. In the TCR ot chain, the threonine at position 2 within 
the conserved GXGT motif adjacent to the predicted CDR3 
region, may be selected in that it is in four of the five se- 
quences and is present in a minority (6/47) of germline Joe 
segments (14). Thus, a wider variety of the TCR genes is 
used in response to this PLP epitope than in response to en- 
cephalitogenic MBP epitopes. TCR 3 chain diversity has also 
been observed with two other encephalitogenic PLP epitopes 
in SJL (15) and in (PL/J  x  SJL)F1 mice (Kuchroo, V. K., 
unpublished data). 
The difference between the limited TCR diversity in re- 
sponse to MBP determinants and the diverse response for PLP 
epitopes could affect susceptibility to EAE induced by these 
two myelin autoantigens. One prediction would be that limi- 
tation of the TCR diversity would have a profound effect 
on the ability of MBP, but not PLP, to induce EAE. We ex- 
amined the ability of encephalitogenic MBP and PLP epi- 
topes to induce EAE in transgenic SJL mice containing a single 
rearranged TCR 3  chain transgene (8,  16). The transgene 
is expressed on >95% of peripheral T cells in the transgenic 
mice.  This transgene, which is not specific for either MBP 
or PLP, was chosen because  the TCR V38.2 is deleted in 
Vc( 
2E5:V~15 ]j~4 
SPL: V~15 ]j~8 
5B6:Va4  J~8 
7A5:V~13 J~27 
4E3:  V~ll ]j~12 
TCR~ ]JUNCTIONAL SEOUENCE 
HITATQPEDSAIYFCAIASPGANTG.KLT]FGHGTILRVHPN 
HITATQPEOSAIYFCAIASTGGNMGYKLTIFGTGTSLLVDPN 
QKASVQESDSAVYFCAIL..VGSMGYKLTIFGTGTSLLVDPN 
KKSPAHWSOSAKYFCA  L..EVSNTDKVVIFGTGTRLQVSPN 
HIROAQLEDSGTYFCA VLYQGGRA..LI FGTGTTVSVSPN 
W  DB  2]]  TCRB JUNCTIONAL SEOUENCE 
2E5:  VI317A O1~1 ]ji]1.2  SSEEDDSALYLCASISLVRGNS.OYTIFGSGTRLLVl 
SPL: V~2  O112 3132.5  VANMSQGRTLYCTC  SAVQGQD.TQYIFGPGTRLLVL 
5B6:V!36  DI~2 3132.6  SAQKNEMAVFLCAS  SRGGRSSYEQY  I FGPGTRLTVL 
7A5:V1310  D132  3~2.4  SVELEDSAVYLCAS  SHWGVQN.TLY FGAGTRLSVL 
4E3:V~16  Dl32 .1132.5  PTALEDSAVYFCAS  SFGGLQD.TQY FGPGTRLLVL 
Figure  1.  Predicted  amino acid sequence of V(D)J junctions of TCR 
oe and 3 chains from PLP-peptide 139-151 specific  T cell clones. Boxed 
residues correspond to predicted  CDR3 regions  (25). The asterisk marks 
the threonine  residue that may be selected  in TCRot. Assignments  to V, 
D, and J segments are based on references (14, 26, 27). Sequence  data are 
available  from EMBL/GenBank/DDBJ  under accession numbers 
(U07653-U07662). 
1660  TCR Use and Susceptibility  in Experimental Autoimmune  Encephalomyelitis Table  1.  Clinical and Histological EAE Induction in SJL  Transgenic and Nontransgenic Mice 
Nontransgenic  Transgenic 
Maximum  Number of  Maximum  Number 
Clinical  Mean day  clinical  inflammatory  Clinical  Mean day  clinical  inflammatory 
Antigen  incidence  of onset  grade  loci  incidence  of onset  grade  foci 
Mouse myelin  8/8  12.1  _+  0.8  3.9  _+  1.0  96  7/7  17.1  +  4.5*  2.6  _+  1.0"  96 
PLP  139-151  4/5  13.3  _+  2.1  3.8  _+  0.5  46  4/5  30.0  _+  10.5"  3.3  -+  1.3  98 
PLP  178-191  4/5  12.3  _+  0.9  3.3  +_  1.5  62  4/6  14.3  _+  1.3  2.8  _+  1.5  70 
MBP 89-101  6/7  16.2  +  6.1  3.7  _+  1.2  45  0/7  -  -  0 
The SJL transgenic and littermate mice were immunized subcutaneously with 2 mg of whole mouse myelin or 150/~g of the individual peptides 
emulsified in CFA, and pertussis toxin as described in Materials and Methods.  Mice were assessed clinically according to following criteria:  0, no 
disease; 1, tail atony; 2,  hind limb weakness and/or poor righting ability; 3, hind limb paralysis; 4,  hind- and fore-limb paralysis; 5, moribund. 
Mice showing clinical signs were killed at the peak of the disease and paraffin-embedded sections were stained with Luxol fast blue-hematoxylin 
and eosin for light microscopy. Disease induction was confirmed and quantified histologically by counting the number of inflammatory loci in the 
white matter in representative mice in each group. Animals were killed within 7-10 d of the initial appearance of clinical signs or at the peak of 
the disease. Mice that show  no clinical signs were  killed 40 d after immunization. 
The data are presented as mean _+  SE. (,) Significant difference (p <0.04-p <0.008)  when compared with values obtained with nontransgenic  litter- 
mates by Student's t test. 
SJL mice (17) and the T cell response to MBP is mediated 
by V/~8.2 in other mouse strains and in Lewis rats (4-6). 
The transgenic mice and the nontransgenic controls that 
were immunized with either mouse myelin or encephalito- 
genic PLP peptides 139-151 or 178-191 developed clinical EAE, 
although the disease occurred earlier and appeared to be more 
severe in the nontransgenic littermates (Table 1). At the peak 
of the disease, however, both groups  had similar numbers 
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Figure 2.  In vitro proliferative response of lymph node cells from SJL 
transgenic and nontransgenic  mice to the encephalitogenic PLP and MBP 
peptides. (A-F) Lymph node cells were isolated from mice immunized 
10-12 d earlier with PLP or MBP peptides in CFA and tested with pep- 
tides at the indicated concentrations. Proliferative responses  were measured 
as described in Materials and Methods. Data from one of the three experi- 
ments is shown. (G and/-/) Lymph node cells were isolated as for A-F, 
incubated with 100/~g of PLP 13%151, and the indicated concentrations 
of anti-TCR V/~ and anti-CD4 antibodies, and proliferation was measured. 
1661  Kuchroo et al.  Brief Definitive Report Figure 3.  Transgenic  and nontransgenic  mice were immunized  with 
PLP-peptide 139-151 in CFA. Brains, spinal cords, and lymphoid  tissues 
were  obtained  at the peak  of  the disease  for histopathological  and immuno- 
histochemical  analysis.  (A) Typical  perivascular  mononuclear  cell  infiltrate 
in a paraffin  section  of the spinal cord of a transgenic  mouse  immunized 
with PLP 139-151. Demyelination  is indicated  by pink staining, whereas 
intact white matter myelin  is stained  blue. Luxol fast blue-hematoxylin 
and eosin, x218. (B) Numerous  TCR Vfl 8  + cells  (arrowheads)  in an acute 
EAE lesion  in the brain of  a Vfl8 transgenic  SJL mouse.  Cryostat  section, 
mAb KJ 16-133 immunoperoxidase  with hematoxylin. ￿  (C) Section 
adjacent  to B stained  with anti-TCR  Vfl4  antibody.  Cryostat  section  anfiVfl4 
with hematoxylin, x340. 
of inflammatory lesions (Table 1). In contrast, immunization 
with the dominant encephalitogenic MBP epitope 89-101 did 
not result in EAE in the transgenic mice, whereas the non- 
transgenic control mice developed typical EAE (Table 1). These 
1662 
results show that limitation of the TCR/3  chain diversity 
to a single/3 chain gene results in loss of susceptibility to 
disease induction by the dominant MBP epitope but not by 
either of the PLP epitopes. 
The difference  in susceptibility to EAE suggested that both 
PLP peptides elicited encephalitogenic T cell responses in the 
transgenic mice, but that the dominant MBP determinant 
did not. We examined in vitro proliferation of lymph node 
T  cells in response to the encephalitogenic determinants of 
MBP and PLP. Lymph node cells from mice immunized with 
PLP peptide proliferated in response to the immunizing PLP 
peptide, but not to other control PLP or MBP peptides. How- 
ever, the proliferative responses of the lymph node cells iso- 
lated from the transgenic mice were reduced by a factor of 
three to four compared with those from nontransgenic con- 
trols (Fig.  2, A-D). In contrast, little or no proliferative re- 
sponse was detected in lymph node cells isolated from trans- 
genic mice immunized with MBP 89-101, despite the strong 
proliferative response observed in lymph node cells from non- 
transgenic littermates (Fig. 2, E and F). Thus, the transgenic 
mice appear to be unable to develop a proliferative T cell re- 
sponse to the dominant MBP determinant 89-101.  TCR-/3 
transgenic mice are unable to recognize some peptides (18) 
probably because of limitation in the available TCR reper- 
toire. This may account for the lack of T  cell response and 
the lack of disease in transgenic mice immunized with MBP 
89-101. 
Non-V/38 § T  cells, which constitute <5% of the total T 
cell pool in the transgenic mice (8), could be responsible for 
the induction of EAE with the encephalitogenic PLP deter- 
minants. The proliferative responses of  lymph node cells from 
transgenic and nontransgenic littermate mice immunized with 
PIP 139-151 were examined in the presence of  anti-V/38 (KJ16) 
mAb. The anti-V/38  mAb blocked the PLP 139-151 specific 
proliferative response of lymph node cells from transgenic 
mice, but not the response of lymph node cells from non- 
transgenic mice. Antibodies to other TCR V/3 chains (V/3 
4, 6,  and 11) did not inhibit the proliferation of transgenic 
lymph node cells in response to PLP 139-151 (Fig. 2, G and 
H).  By immunohistochemistry, the vast majority of the T 
cells in the lymphoid tissue from the transgenic mice expressed 
V/3 8 (~95-99%) with rare, scattered cells expressing some 
of the other TCR V/3  (V/34 and V/36).  In contrast,  lym- 
phoid tissues from the nontransgenic littermates were totally 
devoid of VflS-bearing cells  and expressed larger numbers 
of TCR V/34, V/36, and other TCR V/3s (data not shown). 
Immunocytochemical staining of the inflammatory lesions 
in the CNS of the transgenic mice demonstrated the pres- 
ence of V/38 + cells and virtually no other V/3-bearing  T cells 
(Fig. 3, B and C). Consistent with previous results (19), the 
T cells constituted ~30% of the total inflammatory  cell popu- 
lation in the EAE lesions, which corresponded to the number 
of V/38 + cells detected in the EAE lesions of the transgenic 
mice (Fig.  3 B).  In contrast,  in the nontransgenic control 
mice (which lack V38),  accumulation of T  cells expressing 
various TCR V/3s (V/3 2, 4, 6,  7,  and 14) was seen in the 
infiltrates,  but no TCR V/38-bearing cells were detected (data 
not shown). 
TCR Use and Susceptibility  in Experimental  Autoimmune  Encephalomyelitis Analyses of TCK usage by MBP-specific  T cell clones in 
mice, rats, and humans have suggested a restricted TCK Vl3 
usage (4-6,  20,  21). Both mouse and rat MBP-specific  en- 
cephalitogenic T cell clones use the same Vl3 gene segment 
(V138.2). The "V-region disease hypothesis" (22) proposed 
that TCK V138.2 in association with a specific TCK Vc~ may 
recognize a ligand in the CNS and induce EAE. SJL mice 
do not express a V138.2 gene segment (17), but introduction 
of a V~8.2 transgene into the SJL T cell repertoire provided 
us with a unique opportunity to test the role of this V gene 
in the induction of EAE. Overexpression of a V138.2 trans- 
gene in SJL mice did not permit an immune response to MBP 
89-101 (Fig.  2 F) or development of EAE (Table 1). The T 
cell response to MBP 89-101 is largely mediated by VB17a- 
and V134-bearing cells (23,  24).  Limitation of the TCK 13 
chain repertoire to a single rearranged 13 chain does not permit 
development of an immune response to this encephalitogenic 
MBP epitope. In contrast, the severe limitation on TCK IS 
chain diversity does not prevent a  T  cell response to en- 
cephalitogenic PLP epitopes or the induction of EAE in a 
susceptible mouse strain. T cells using the novel rearranged 
TCK/3 chain are therefore able to recognize the encephalito- 
genic PLP epitopes and induce EAE. Although the autoan- 
tigen(s) involved in MS has not been identified, PLP could 
be involved in pathogenesis of MS. Our data would suggest 
that T cell responses to PLP epitopes may differ from those 
to MBP epitopes and that this finding should be considered 
in the design of TCK-based therapies for MS. 
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